Polymyalgia Rheumatica
Updated: 05/12/2006
References
Abdel-Salam OM, Baiuomy AR, et al. The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol Res. 2003 Apr;47(4):331–40.
Adachi JD, Olszynski WP, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000a Feb;29(4):228–51.
Adachi JD, Roux C, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol. 2000b Oct;27(10):2424–31.
Aggarwal BB, Shishiodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: Reasoning for seasoning. Ann N Y Acad Sci. 2004 Dec;1030:434–41.
Aksu K, Turgan N, et al. Hyperhomocysteinaemia in Behcet’s disease. Rheumatology (Oxford). 2001 Jun;40(6):687–90.
Barilla-LaBarca ML, Lenschow DJ, et al. Polymyalgia rheumatica/temporal arteritis: Recent advances. Curr Rheumatol Rep. 2002 Feb;4(1):39–46.
Baumann B, Bohnenstengel F, et al. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J Biol Chem. 2002 Nov 22;277(47):44791–800.
Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Available at: http://www.merck.com/mrkshared/mmanual/home.jsp. Accessed March 15, 2006.
Bern M. Observations on possible effects of daily vitamin K replacement, especially upon warfarin therapy. J Parenter Enteral Nutr. 2004 Nov-Dec;28(6):388–98.
Bowie AG, O’Neill LA. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol. 2000 Dec 15;165(12):7180–8.
Brito J, Biamonti G, et al. Autoantibodies to human nuclear lamin B2 protein: Epitope specificity in different autoimmune diseases. J Immunol. 1994 Sep 1;153(5):2268–77.
Calzado MA, Ludi KS, et al. Inhibition of NF-kappaB activation and expression of inflammatory mediators by polyacetylene spiroketals from Plagius flosculosus. Biochim Biophys Acta. 2005 Jun 30;1729(2):88–93.
Cantini F, Niccoli L, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum. 2004 Apr;33(5):294–301.
Caporali R, Cimmino MA, et al. Prednisone plus methotrexate for polymyalgia rheumatica: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004 Oct 5;141(7):493–500.
Chang RW, Fineberg HV. Risk-benefit considerations in the management of polymyalgia rheumatica. Med Decis Making. 1983;3(4):459–75.
Cimmino MA. Genetic and environmental factors in polymyalgia rheumatica. Ann Rheum Dis. 1997 Oct;56(10):576–7.
Cutolo M, Foppiani L, et al. Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest. 2002a;25(10 Suppl):19–23.
Cutolo M, Straub RH, et al. Adrenal gland hypofunction in active polymyalgia rheumatica: Effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J Rheumatol. 2002b Apr;29(4):748–56.
Das UN. Nutrients, essential fatty acids and prostaglandins interact to augment immune responses and prevent genetic damage and cancer. Nutrition. 1989 Mar-Apr;5(2):106–10.
de la Torre B, Fransson J, et al. Blood dehydroepiandrosterone sulphate (DHEAS) levels in pemphigoid/pemphigus and psoriasis. Clin Exp Rheumatol. 1995 May-Jun;13(3):345–8.
Dolan AL, Moniz C, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum. 1997 Nov;40(11):2022–9.
Dorazil-Dudzik M, Mika J, et al. The effects of local pentoxifylline and propentofylline treatment on formalin-induced pain and tumor necrosis factor-alpha messenger RNA levels in the inflamed tissue of the rat paw. Anesth Analg. 2004 Jun;98(6):1566–73.
Eichbaum FW, Slemer O, et al. Anti-inflammatory effect of warfarin and vitamin K1. Naunyn Schmiedebergs Arch Pharmacol. 1979 Jun 18;307(2):185–90.
Endres S, Ghorbani R, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989 Feb 2;320(5):265–71.
Ferraccioli GF, Di Poi E, et al. Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis: State of the art and perspectives. Clin Exp Rheumatol. 2000 Jul-Aug;18(4 Suppl 20):S58–S60.
Gennari R, Alexander JW. Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. Crit Care Med. 1997 Jul;25(7):1207–14.
Gerster JC, So AK, et al. [Systemic corticosteroid therapy in rheumatology, advantages and risks]. Schweiz Rundsch Med Prax. 1998 Aug 12;87(33):1024–7.
Gitlits VM, Macaulay SL, et al. Novel human autoantibodies to phosphoepitopes on mitotic chromosomal autoantigens (MCAs). J Investig Med. 2000 May;48(3):172–82.
Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: Two different but often overlapping conditions. Semin Arthritis Rheum. 2004 Apr;33(5):289–93.
Gonzalez-Gay MA, Amoli MM, et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003 Aug;33(1):38–48.
Graninger W, Wenisch C. Pentoxifylline in severe inflammatory response syndrome. J Cardiovasc Pharmacol. 1995;25 Suppl 2:S134–S138.
Guthikonda S, Haynes WG. Homocysteine: Role and implications in atherosclerosis. Curr Atheroscler Rep. 2006 Mar;8(2):100–6.
Hellmich B, Gross WL. [Polymyalgia rheumatica: Myalgic syndrome or occult vasculitis?] Internist (Berl). 2005 Nov;46(11):1233–44.
Ho LJ, Juan TY, et al. Plant alkaloid tetrandrine downregulates IkappaBalpha kinases-IkappaBalpha-NF-kappaB signaling pathway in human peripheral blood T cell. Br J Pharmacol. 2004 Dec;143(7):919–27.
Honing ML, Bredie SJ, et al. [Aortic involvement in patients with temporal arteritis and polymyalgia rheumatica.] Ned Tijdschr Geneeskd. 2005 Aug 27;149(35):1947–53.
Horvath K, Noker PE, et al. Toxicity of methylsulfonylmethane in rats. Food Chem Toxicol. 2002 Oct;40(10):1459–62.
Ichikawa H, Takada Y, et al. Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappa B-regulated gene products. J Immunol. 2005 Jun 1;174(11):7383–92.
Jobin C, Bradham CA, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999 Sep 15;163(6):3474–83.
Kelley DS. Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition. 2001 Jul-Aug;17(7–8):669–73.
Kim LS, Axelrod LJ, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: A pilot clinical trial. Osteoarthritis Cartilage. 2006 Mar;14(3):286–94.
Labbe P, Hardouin P. Epidemiology and optimal management of polymyalgia rheumatica. Drugs Aging. 1998 Aug;13(2):109–18.
Lin SL, Chiang WC, et al. The renoprotective potential of pentoxifylline in chronic kidney disease. J Chin Med Assoc. 2005 Mar;68(3):99–105.
Lyss G, Schmidt TJ, et al. Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kappaB. Biol Chem. 1997 Sep;378(9):951–61.
Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol. 2001 Sep 1;167(5):2911–20.
Mandell GL. Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol. 1995;25 Suppl 2:S20–S22.
Manna SK, Mukhopadhyay A, et al. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 2000a Jun 15;164(12):6509–19.
Manna SK, Sah NK, et al. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res. 2000b Jul 15;60(14):3838–47.
McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses. 1999 May;52(5):465–77.
McGonagle D, Pease C, et al. Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J Rheumatol. 2001 Aug;28(8):1837–41.
Meliconi R, Pulsatelli L, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica: Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum. 1996 Jul;39(7):1199–207.
Meno-Tetang GM, Blum RA, et al. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. J Clin Pharmacol. 2001 Nov;41(11):1195–205.
Meyer O, Nicaise P, et al. Antibodies to cardiolipin and beta 2 glycoprotein I in patients with polymyalgia rheumatica and giant cell arteritis. Rev Rhum Engl Ed. 1996 Apr;63(4):241–7.
Migliore A, Massafra U, et al. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: A seven cases report. Eur Rev Med Pharmacol Sci. 2005 Nov-Dec;9(6):373–8.
Narvaez J, Narvaez JA, et al. Giant cell arteritis and polymyalgia rheumatica: Usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology (Oxford). 2005 Apr;44(4):479–83.
Neuner P, Klosner G, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology. 1994 Oct;83(2):262–7.
Nilsson E, de la Torre B, et al. Blood dehydroepiandrosterone sulphate (DHEAS) levels in polymyalgia rheumatica/giant cell arteritis and primary fibromyalgia. Clin Exp Rheumatol. 1994 Jul-Aug;12(4):415–7.
Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev. 2002 Feb;7(1):22–44.
Pavlica P, Barozzi L, et al. Magnetic resonance imaging in the diagnosis of PMR. Clin Exp Rheumatol. 2000 Jul-Aug;18(4 Suppl 20):S38–9.
Petri MA, Lahita RG, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002 Jul;46(7):1820–9.
Pollice PF, Rosier RN, et al. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: A potential treatment for aseptic loosening of total joint components. J Bone Joint Surg Am. 2001 Jul;83-A(7):1057–61.
Reginster JY, Lecart MP, et al. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss. J Rheumatol Suppl. 2005 Sep;76:21–5.
Richmond VL. Incorporation of methylsulfonylmethane sulfur into guinea pig serum proteins. Life Sci. 1986 Jul 21;39(3):263–8.
Richy F, Schacht E, et al. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcif Tissue Int. 2005 Mar;76(3):176–86.
Riehemann K, Behnke B, et al. Plant extracts from stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the proinflammatory transcription factor NF-kappaB. FEBS Lett. 1999 Jan 8;442(1):89–94.
Salvarani C, Cantini F, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med. 1997 Jul 1;127(1):27–31.
Salvarani C, Cantini F, et al. Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study. J Rheumatol. 2003 Apr;30(4):760–3.
Salvarani C, Cantini F, et al. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol. 2004 Oct;18(5):705–22.
Samanta A, Kendall J. A fresh look at polymyalgia rheumatica. Rheumatology (Oxford). 2002 Dec;41(12):1455–6.
Schmits R, Kubuschok B, et al. Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol. 2002 Feb;127(2):379–85.
Shibanuma M, Kuroki T, et al. Inhibition by N-acetyl-L-cysteine of interleukin-6 mRNA induction and activation of NF kappa B by tumor necrosis factor alpha in a mouse fibroblastic cell line, Balb/3T3. FEBS Lett. 1994 Oct 10;353(1):62–6.
Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999 Sep;70(3 Suppl):560S–569S.
Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002 Dec;21(6):495–505.
Singh U, Devaraj S, et al. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr. 2005;25:151–74.
Straub RH, Gluck T, et al. The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford). 2000a Jun;39(6):624–31.
Straub RH, Konecna L, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: Possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab. 1998 Jun;83(6):2012–7.
Straub RH, Scholmerich J, et al. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases: Substitutes of adrenal and sex hormones. Z Rheumatol. 2000b;59 Suppl 2:II/108–18.
Sunder-Plassmann G, Winkelmayer WC, et al. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease. Expert Opin Investig Drugs. 2000 Nov;9(11):2637–51.
Tidow-Kebritchi S, Mobarhan S. Effects of diets containing fish oil and vitamin E on rheumatoid arthritis. Nutr Rev. 2001 Oct;59(10):335–8.
Tortora GJ, Grabowski SR. Principles of Anatomy and Physiology. 10th ed. New York: John Wiley & Sons, Inc.; 2003.
Turbin RE, Kupersmith MJ. Giant cell arteritis. Curr Treat Options Neurol. 1999 Mar;1(1):49–56.
Venkatraman JT, Chu WC. Effects of dietary omega3 and omega6 lipids and vitamin E on proliferative response, lymphoid cell subsets, production of cytokines by spleen cells, and splenic protein levels for cytokines and oncogenes in MRL/MpJ-lpr/lpr mice. J Nutr Biochem. 1999a Oct;10(10):582–97.
Venkatraman JT, Chu WC. Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr. 1999b Dec;18(6):602–13.
Villareal DT, Holloszy JO, et al. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf). 2000 Nov;53(5):561–8.
Whan HJ, Gon LB, et al. Ergolide, sesquiterpene lactone from Inula britannica, inhibits inducible nitric oxide synthase and cyclo-oxygenase-2 expression in RAW 264.7 macrophages through the inactivation of NF-kappaB. Br J Pharmacol. 2001 Jun;133(4):503–12.
Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003 Sep 16;139(6):505–15.
Weyand CM, Ma-Krupa W, et al. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004 Jan;3(1):46–53.
Yadav VS, Mishra KP, et al. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol. 2005;27(3):485–97.
Zlonis M. The mystique of the erythrocyte sedimentation rate: A reappraisal of one of the oldest laboratory tests still in use. Clin Lab Med. 1993 Dec;13(4):787–800.